文献速递生殖医学

保险强制令对供卵使用的影响:基于辅助生殖技术注册库39,338个供卵周期的分析

The impact of insurance mandates on donor oocyte utilization: an analysis of 39,338 donor oocyte cycles from the Society for Assisted Reproductive Technology registry.
PubMed 文献 · Am J Obstet Gynecol · 2022-07-19

该回顾性队列研究利用美国辅助生殖技术注册库2014年1月1日至2016年12月31日的数据,分析39,338个供卵周期和242,555个自体卵母细胞周期,按所在州保险强制令状态分层。结果发现无强制令州患者在使用供卵前接受的自体辅助生殖技术周期数更少,且更倾向于使用冷冻供卵,但供卵受者的临床妊娠率和活产率在各保险强制令状态间相似。

要点

  • 无强制令州患者使用供卵前平均接受1.1个自体辅助生殖技术周期,少于部分覆盖州(1.7个)和全面覆盖州(1.7个)。
  • 无强制令州患者使用冷冻供卵的可能性高于部分覆盖州(相对风险0.54)和全面覆盖州(相对风险0.94)。
  • 供卵受者的临床妊娠率和活产率在各保险强制令状态间相似。

核心结论

  • 尽管年龄和卵巢储备参数相似,无州保险强制令覆盖辅助生殖技术的患者比部分或全面覆盖州的患者更可能使用冷冻供卵,且接受的自体体外受精周期数更少。
  • 供卵使用的这些差异凸显了在无保险覆盖州寻求辅助生殖技术相关的经济障碍。

研究设计与样本

  • 回顾性队列研究,使用美国辅助生殖技术注册库2014年1月1日至2016年12月31日的数据,纳入39,338个供卵周期和242,555个自体卵母细胞周期。
  • 周期按实施辅助生殖技术所在州的保险强制令状态分层:全面覆盖(覆盖至少4个辅助生殖技术周期)、部分覆盖(覆盖1-3个辅助生殖技术周期)、仅提供(存在保险强制令但排除辅助生殖技术治疗)和无强制令。
  • 主要结局为受者既往自体辅助生殖技术周期数;次要结局包括年龄、血清促卵泡激素水平、冷冻供卵使用、胚胎移植日、移植胚胎数、临床妊娠率和活产率。
  • 分析对移植日、移植胚胎数和受者年龄进行了调整。

主要发现

  • 无强制令州患者使用供卵前接受的自体辅助生殖技术周期数(均值1.1,标准差1.6)少于仅提供州(均值1.7,标准差2.5;P<.01)、部分覆盖州(均值1.5,标准差2.5;P<.01)和全面覆盖州(均值1.7,标准差2.0;P<.01)。
  • 无强制令州患者使用冷冻卵母细胞的可能性高于仅提供州(相对风险0.54;95%置信区间0.52-0.57)、部分覆盖州(相对风险0.50;95%置信区间0.46-0.54)和全面覆盖州(相对风险0.94;95%置信区间0.89-0.99)。
  • 供卵受者的临床妊娠率和活产率在各保险强制令状态间相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A total of 19 states passed legislation mandating insurance coverage of assisted reproductive technology, and out-of-pocket costs associated with in vitro fertilization vary significantly depending on the region. Consequently, it has been observed that assisted reproductive technology utilization differs regionally and is associated with the presence of an insurance mandate. However, it is unknown whether regional differences exist among patients using donor oocytes. OBJECTIVE: This study aimed to determine the patient and cycle-specific parameters associated with the use of donor oocytes according to the insurance mandate status of the Society for Assisted Reproductive Technology clinic in which the assisted reproductive technology cycle was performed. STUDY DESIGN: This study was a retrospective cohort study using national data collected from the Society for Assisted Reproductive Technology registry for 39,338 donor oocyte cycles and 242,555 autologous oocyte cycles performed in the United States from January 1, 2014, to December 31, 2016. Cycles were stratified by insurance mandate of the state in which the assisted reproductive technology cycle was performed: comprehensive (coverage for at least 4 cycles of assisted reproductive technology), limited (coverage limited to 1-3 assisted reproductive technology cycles), offer (insurance mandates exist but exclude assisted reproductive technology treatment), and no mandate. The primary outcome was the number of previous autologous assisted reproductive technology cycles of the recipient. The secondary outcomes included age, serum follicle stimulating hormone level, frozen donor oocyte utilization, day of embryo transfer, number of embryos transferred, clinical pregnancy rate, and live birth rate. Analyses were adjusted for day of transfer, number of embryos transferred, and age of the recipient. RESULTS: Patients in no mandate states underwent fewer autologous assisted reproductive technology cycles (mean, 1.1; standard deviation, 1.6) before using donor oocytes than patients in offer (mean, 1.7; standard deviation, 2.5; P<.01), limited (mean, 1.5; standard deviation, 2.5; P<.01), and comprehensive (mean, 1.7; standard deviation, 2.0; P<.01) states. Patients in no mandate states were more likely to use frozen oocytes than patients in offer (relative risk, 0.54; 95% confidence interval, 0.52-0.57), limited (relative risk, 0.50; 95% confidence interval, 0.46-0.54), and comprehensive (relative risk, 0.94; 95% confidence interval, 0.89-0.99) states. Clinical pregnancy and live birth rates were similar among recipients of donor oocytes, regardless of insurance mandate. CONCLUSION: Despite similar ages and ovarian reserve parameters, patients without state-mandated insurance coverage of assisted reproductive technology were more likely to use frozen donor oocytes and undergo fewer autologous in vitro fertilization cycles than their counterparts in partial or comprehensive insurance coverage states. These differences in donor oocyte utilization highlight the financial barriers associated with pursuing assisted reproductive technology in uninsured states.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. George JS, Lee MS, Ashby RK, et al. The impact of insurance mandates on donor oocyte utilization: an analysis of 39,338 donor oocyte cycles from the Society for Assisted Reproductive Technology registry. Am J Obstet Gynecol. 2022. PMID: 35863456. doi:10.1016/j.ajog.2022.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。